Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe hidden links between hormones and lung disease

NCT ID NCT01884051

Knowledge-focused Sponsor: Vanderbilt University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at how hormones and metabolism are involved in pulmonary arterial hypertension (PAH), a serious lung condition. Researchers will measure sex hormone levels, insulin resistance, and test two potential treatments—metformin and ACE-2—in small groups. The goal is to understand the disease better and find new ways to treat it.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Metformin, ACE-2
What this could lead to
If successful, this could point toward new treatments for pulmonary arterial hypertension by targeting metabolic and hormonal pathways.
What could go wrong
This is an early-stage, observational study with multiple exploratory aims. The findings may not lead to a proven therapy, and the interventions tested (metformin, ACE-2) may not show benefit or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,899 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Sep 2012

Expected to finish

Jul 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Cohort 1 subjects will be recruited from our adult and pediatric pulmonary vascular disease clinics. Cohort 2-healthy controls will be recruited form patients families and the general public in middle Tennesssee.

Ages

Up to 90 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Project 1 Inclusion: 1. Diagnosis of IPAH (idiopathic pulmonary arterial hypertension), HPAH (heritable pulmonary arterial hypertension), or APAH (associated pulmonary arterial hypertension), family members of affected persons 2. Age 0-90, age 12-90 for skin biopsy Exclusion: 1. Other diagnosis 2. Age greater than 90, age less than 12 or greater than 90 for skin biopsy Project 2 Inclusion: 1. Diagnosis of IPAH, HPAH, or APAH, family members of affected persons 2. 0-90 3. Subjects with reasonably easy access to clinic for blood collection and other testing 4. Subject able to tolerate fasting state prior to sample collection and EndoPAT (endothelial function assessment) testing Exclusion: 1. Other diagnosis 2. 0-90 3. Subjects with difficulty reaching clinic for blood collection and other testing 4. Subjects unable to tolerate fasting state Project 3 Inclusion: 1. Diagnosis of IPAH, HPAH, or APAH, family members of affected persons 2. 7-90 Exclusion: 1. Other diagnosis 2. Age less than 7 or greater than 90 \- Exclusion Criteria: \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Appetite suppressant associate PAH are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

drug- or toxin-induced pulmonary arterial hypertension Familial Primary Pulmonary Hypertension heritable pulmonary arterial hypertension idiopathic pulmonary arterial hypertension pulmonary arterial hypertension pulmonary systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Appetite suppressant associate PAH Heritable pulmonary arterial hypertension Idiopathic pulmonary arterial hypertension Scleroderma associated pulmonary arterial hypertension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Vanderbilt University Medical Center

    RECRUITING

    Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.